SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 26 10 2020
accepted: 07 01 2021
pubmed: 12 1 2021
medline: 9 3 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

Characterization of the T cell response in individuals who recover from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its contribution to protective immunity. A multiplexed peptide-MHC tetramer approach was used to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition in a cross-sectional sample of 30 coronavirus disease 2019 convalescent individuals. T cells were evaluated using a 28-marker phenotypic panel, and findings were modelled against time from diagnosis and from humoral and inflammatory responses. There were 132 SARS-CoV-2-specific CD8+ T cell responses detected across 6 different HLAs, corresponding to 52 unique epitope reactivities. CD8+ T cell responses were detected in almost all convalescent individuals and were directed against several structural and nonstructural target epitopes from the entire SARS-CoV-2 proteome. A unique phenotype for SARS-CoV-2-specific T cells was observed that was distinct from other common virus-specific T cells detected in the same cross-sectional sample and characterized by early differentiation kinetics. Modelling demonstrated a coordinated and dynamic immune response characterized by a decrease in inflammation, increase in neutralizing antibody titer, and differentiation of a specific CD8+ T cell response. Overall, T cells exhibited distinct differentiation into stem cell and transitional memory states (subsets), which may be key to developing durable protection.

Identifiants

pubmed: 33427749
pii: 145476
doi: 10.1172/JCI145476
pmc: PMC7919723
doi:
pii:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
HLA Antigens 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI152078
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120938
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059842
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI052733
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128779
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL151826
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR005228
Pays : United States

Références

Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Sci Immunol. 2017 Jun 2;2(12):
pubmed: 28783656
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Nat Commun. 2018 Jul 26;9(1):3000
pubmed: 30050138
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
PLoS Pathog. 2013;9(6):e1003422
pubmed: 23818845
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Immunother Cancer. 2019 Sep 12;7(1):249
pubmed: 31511069
Sci Rep. 2020 Nov 24;10(1):20465
pubmed: 33235258
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Biotechnol. 2013 Jul;31(7):623-9
pubmed: 23748502
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
J Exp Med. 1999 Sep 6;190(5):705-15
pubmed: 10477554
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Open Forum Infect Dis. 2020 Nov 26;8(2):ofaa574
pubmed: 33553467
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330

Auteurs

Hassen Kared (H)

ImmunoScape, Singapore, Singapore.

Andrew D Redd (AD)

Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Department of Medicine and.

Evan M Bloch (EM)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Tania S Bonny (TS)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Hermi Sumatoh (H)

ImmunoScape, Singapore, Singapore.

Faris Kairi (F)

ImmunoScape, Singapore, Singapore.

Daniel Carbajo (D)

ImmunoScape, Singapore, Singapore.

Brian Abel (B)

ImmunoScape, Singapore, Singapore.

Evan W Newell (EW)

ImmunoScape, Singapore, Singapore.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Maria P Bettinotti (MP)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Sarah E Benner (SE)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Eshan U Patel (EU)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Epidemiology and.

Kirsten Littlefield (K)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Oliver Laeyendecker (O)

Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Department of Medicine and.

Shmuel Shoham (S)

Department of Medicine and.

David Sullivan (D)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Arturo Casadevall (A)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Andrew Pekosz (A)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Alessandra Nardin (A)

ImmunoScape, Singapore, Singapore.

Michael Fehlings (M)

ImmunoScape, Singapore, Singapore.

Aaron Ar Tobian (AA)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Thomas C Quinn (TC)

Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Department of Medicine and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH